Scope and Claims Analysis for U.S. Patent 11,084,780: Crystalline, Amorphous, Form-Specific XRPD Protection for N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide (FIPFA/IPGA Coupling Route)
Executive summary. U.S. Patent 11,084,780 is a solid-state IP estate built around (1) polymorph/form-specific protection for a single named drug substance (Formula I) using XRPD fingerprint windows, (2) coverage for amorphous material, (3) composition claims (drug substance plus carrier, with a tight limit on other forms), and (4) process claims tying the target API to a specific coupling sequence between PD-0315209 (FIPFA) and PD-0337792 (IPGA) using T3P (1-propylphosphonic anhydride) followed by acid deprotection/conversion from an intermediate “901 Acetonide.” Commercially, the claim set is designed to block generic entry via (a) supplying a non-infringing form only if it falls outside the enumerated XRPD windows and other-form thresholds, and (b) avoiding infringement of the manufacturing route unless the generic can credibly change both the reagents and the sequence such that it does not practice the claimed steps.
What are the key claim categories in U.S. Patent 11,084,780?
Direct answer. The patent divides into five enforceable hooks: (i) XRPD-defined crystalline forms (Form I-like “selected from” list), (ii) amorphous solid, (iii) pharmaceutical compositions with quantitative control of other solid forms, (iv) tablet/capsule/dosage-form dependent composition claims, and (v) synthesis method claims anchored to the FIPFA + IPGA coupling using T3P, including the intermediate “901 Acetonide” and acid conversion.
Claim map (what each group protects)
| Claim(s) |
Claim subject |
Legal scope lever |
Practical entry risk it targets |
| 1 |
Crystalline forms of Formula (I) “selected from” multiple XRPD patterns (a–t) |
Strong for form-specific infringement; enumerates multiple alternative XRPD fingerprints |
Generic producing a different polymorph may be outside, but most “form screening” often lands near some licensed fingerprint; also “essentially pure” later tightens |
| 2 |
Amorphous solid of Formula (I) |
Covers non-crystalline state |
Generic using amorphous dispersion directly risks infringement even if crystalline form differs |
| 3–7 |
Pharmaceutical composition with crystalline form or amorphous solid + carrier; includes dosage forms (capsule/tablet/powder/granules/minitablet/pellet) |
Broad end-use coverage if any protected solid is included |
Blocks formulation-only “workarounds” if solid-state selection matches claims |
| 4 |
Composition where protected solid has <10% by weight total of other crystalline forms/amorphous solid |
Limits polymorph mixture tolerance |
Even if a generic uses a different polymorph, mixing above the threshold can become infringing |
| 5–7 |
Capsule/tablet/powder etc; tablet must be dispersible; formulation narrowing |
Narrows but increases enforcement power against specific dosage platforms |
Entry risk if ANDA targets a dispersible tablet platform using protected solid-state |
| 8–12 |
Method producing Formula (I): FIPFA + IPGA + T3P to obtain “901 Acetonide,” then treat with acid |
Process claims tied to specific reactants, coupling reagent, and Scheme steps |
Harder for ANDA if route differs, but route must be fully redesigned to avoid literal and potentially doctrine-of-equivalents practice |
| 13–14 |
“Essentially pure” Form IV composition; ≤0.2% dimeric impurity PF-00191189 |
Combination of form identity + impurity specification |
Provides an impurity-controlled enforcement hook; forces compliance with tight QC in product lots |
| 15 |
Composition prepared by method of claim 8 |
Backstops to process-to-product |
If a product is made by that exact method, composition is protected even if end-form isn’t argued solely from XRPD |
How broad is Claim 1’s crystalline-form coverage under the XRPD windows?
Direct answer. Claim 1 is broad across multiple alternative crystalline forms, but each alternative is narrowly defined by an XRPD peak list with ±0.2° two-theta tolerances. Infringement can occur if the accused crystalline material is characterized by one of the enumerated XRPD peak patterns (a–t) within the stated windows.
What the claim language does strategically
- “Selected from the group consisting of …” creates multiple distinct embodiments. Each enumerated XRPD fingerprint is effectively a separate infringing species.
- XRPD windows are not generic “XRD peaks around.” They specify exact peaks with specific tolerance bands (±0.2°). This creates defensible boundaries but also means that a competitor can inadvertently fall into one of the enumerated patterns during polymorph development.
- Peak sets vary by embodiment size and identity. Some embodiments list four peaks; others list three; others list smaller sets. This affects detectability and whether an accused product can argue mismatching patterns.
Practical interpretive consequence for enforcement
- If a generic files with a solid form that is characterized as one of the XRPD fingerprints within tolerances, Claim 1 is directly triggered regardless of process.
- If the generic avoids Claim 1 by selecting a non-matching XRPD pattern, it still faces Claim 2 (amorphous) and composition downstream claims (3–7, 4’s <10% other forms cap).
- The existence of “Form IV” in Claim 13/14 adds an additional enforcement layer beyond Claim 1: even if XRPD is argued, “essentially pure” plus impurity constraint can be used as a compliance shield.
What crystalline forms are enumerated in Claim 1, and how many embodiments are covered?
Direct answer. Claim 1 enumerates 20 crystalline-form embodiments identified as XRPD pattern alternatives labeled a through t.
Enumerated XRPD alternatives (a–t)
Claim 1 covers crystalline Form (or crystalline form embodiment) of Formula (I) with XRPD peaks at the following two-theta values (degrees), each with ±0.2° tolerance, for each labeled embodiment:
- a) 5.4, 12.5, 17.5, 22.8
- b) 5.9, 7.2, 9.3, 21.2
- c) 5.3, 10.6, 13.9, 16.1
- d) 5.4, 10.7, 18.7, 23.9
- e) 6.7, 13.5, 22.2
- f) 5.5, 10.6, 19.6, 24.8
- g) 5.5, 6.9, 10.1, 19.2
- h) 10.1, 17.3, 21.5, 22.6
- i) 4.6, 5.1, 6.4, 14.6
- j) 4.6, 23.4, 25.2
- k) 5.5, 14.7, 20.9, 26.6
- l) 6.0, 12.8, 17.1, 20.6
- m) 5.9, 10.1, 11.7, 15.5
- n) 4.6, 10.7, 15.9, 19.6
- o) 10.2, 11.6, 20.0
- p) 7.8, 14.0, 15.6, 17.1
- q) 5.5, 8.2, 16.7, 17.7
- r) 7.2, 21.7, 29.1
- s) 5.4, 6.5, 9.7, 10.7
- t) 7.2, 20.6, 23.0
Does Claim 2 add meaningful coverage beyond Claim 1?
Direct answer. Yes. Claim 2 covers amorphous solid of Formula (I), which is distinct from crystalline polymorph coverage in Claim 1. A competitor can attempt to avoid Claim 1 by using a non-enumerated crystalline form, but Claim 2 can still capture amorphous material unless the generic also avoids presenting an amorphous solid as such.
How amorphous coverage interacts with Claim 4
Claim 4’s <10% by weight limitation on other forms applies to “the crystalline form or the amorphous solid” in Claim 3. That means a generic formulating amorphous material still must keep total other forms below the threshold to avoid infringement of Claim 4 specifically, even if Claim 2 is already met.
What do Claims 3 and 4 protect in terms of formulation and polymorph purity?
Direct answer. Claim 3 covers any pharmaceutical composition comprising the protected crystalline form (Claim 1) or amorphous solid (Claim 2) plus a pharmaceutically acceptable carrier. Claim 4 adds a purity restriction: the composition must contain less than 10% by weight of one or more other crystalline forms and/or amorphous solid.
Claim 4 as an enforcement “tripwire”
- If a competitor’s final solid dispersion or tablet contains a mixture of protected solid state plus other polymorphs, the <10% threshold becomes measurable.
- It can be used both as a validity-supporting limitation (tightens what counts as infringing composition) and as a litigation target (batch-specific analytical results).
Dosage form scope under Claims 5–7
Claim 5 defines broad dosage presentations: capsule, tablet, powder, granules, minitablet, pellet. Claim 6 narrows to tablets. Claim 7 narrows further to dispersible tablets, making it a focused sub-species for certain commercialization strategies.
What manufacturing route is claimed under Claims 8–12, and where are the infringement-critical steps?
Direct answer. Claims 8–12 protect a specific synthetic sequence:
- React PD-0315209 (FIPFA) and PD-0337792 (IPGA) using T3P (1-propylphosphonic anhydride) to obtain “901 Acetonide”
- Treat the intermediate with acid to form the target compound of Formula (I).
Claim 8 core elements
- Reactants: PD-0315209 (FIPFA) + PD-0337792 (IPGA)
- Coupling reagent: T3P
- Product formation: target Formula (I) per Scheme 1
Dependent constraints (Claims 9–12)
- Claim 9: T3P is provided “in solution”
- Claim 10: T3P in solution is provided “in ethyl acetate”
- Claim 11: Explicit two-step structure (a) coupling to obtain 901 Acetonide then (b) acid conversion to Formula (I)
- Claim 12: Alternate phrasing of two-step structure also tied to Scheme III but still anchored to coupling reagent and acid conversion
Infringement-criticality
- The process claims are strongest where an accused manufacturer replicates both: (i) the reactant pair and (ii) the use of T3P and (iii) the intermediate pathway to 901 Acetonide followed by acid conversion.
- A design-around that changes only solvent (e.g., not ethyl acetate) may avoid Claims 10 specifically, but not necessarily Claims 8 or 11 depending on how broad the evidence is for the actual coupling conditions.
What does Claim 13 add with “essentially pure Form IV” and impurity control (Claim 14)?
Direct answer. Claim 13 protects a crystalline composition that is “essentially pure Form IV” prepared by the method of Claim 8. Claim 14 tightens it further by requiring ≤0.2% dimeric impurity PF-00191189.
Why this is commercially relevant
- Competitors can potentially produce a crystalline product that matches Claim 1 XRPD fingerprints, but Claim 13 targets a specific form designation (“Form IV”) and couples it to the process of Claim 8.
- The impurity ceiling in Claim 14 gives another infringement axis: even if polymorph is right, failure to meet the impurity specification can be litigated as non-infringement. Conversely, if the accused product is well-controlled and meets the limit, claim strength increases.
How do Claim 15’s process-to-product concepts expand enforcement?
Direct answer. Claim 15 protects “a composition of Formula (I) prepared by the method of claim 8.” This is a classic process-to-product backup. It can matter when an accused composition’s XRPD characterization is disputed or when litigation focuses on whether a product lot was made using the claimed route.
What patent landscape issues are implicated by this claim set (and what risks do they create for generics)?
Direct answer. Even without additional patents identified here, the claim architecture indicates a landscape built around solid-state variants and a specific coupling route. This raises three high-probability entry risks:
- Form-screening risk: many solid-state development efforts land near known XRPD patterns; enumerated peaks make accidental overlap plausible.
- Amorphous route risk: if the ANDA uses amorphous material to improve solubility or manufacturability, Claim 2 can block entry.
- Route replication risk: if the ANDA API is made via FIPFA + IPGA coupling using T3P and the 901 Acetonide intermediate, process claims become a parallel infringement theory.
Landscape-style litigation posture implied by the claims
- The patent supports both substance theories (Claim 1/2 and compositions Claim 3–7) and manufacturing theories (Claims 8–12 and process-to-product Claim 15).
- The combination of XRPD identification and process steps is a common structure in solid-form portfolios where the patent holder expects both product and manufacturing defenses to arise.
Key Takeaways
- U.S. Patent 11,084,780 protects one specific drug substance (Formula I) via enumerated XRPD-defined crystalline embodiments (a–t) plus amorphous solid coverage.
- Form freedom is limited: Claim 4 restricts mixtures by requiring <10% by weight of other solid forms/amorphous in the final composition.
- Formulation scope extends to common dosage units, culminating in dispersible tablets.
- The process claims anchor infringement to a T3P-mediated coupling of FIPFA (PD-0315209) and IPGA (PD-0337792) to form 901 Acetonide, followed by acid conversion to the target API.
- “Essentially pure Form IV” plus a tight PF-00191189 impurity ceiling (≤0.2%) provides a high-value enforcement lever tied to both identity and quality control.
FAQs
1) Does U.S. Patent 11,084,780 cover any crystalline form, or only the listed XRPD embodiments?
It covers crystalline forms only to the extent they match one of the XRPD peak patterns explicitly enumerated in Claim 1 (a through t), each within the stated ±0.2° two-theta tolerance.
2) Can a competitor avoid infringement by switching from a listed crystalline form to a different polymorph?
Potentially for Claim 1, if the new polymorph does not match any listed XRPD pattern. But infringement risks remain via Claim 2 (amorphous) and Claim 4’s <10% mixture constraint, plus potential process-to-product coverage if made by the claimed method.
3) Is solvent choice protected under these claims?
Only indirectly. Claims 9 and 10 specify that T3P is in solution and, in Claim 10, that it is in ethyl acetate. Avoiding ethyl acetate may avoid Claim 10 specifically but does not necessarily avoid broader process claims (Claims 8, 11, 12).
4) What is the role of PF-00191189 in Claim 14?
It sets an impurity limit: the essentially pure Form IV crystalline composition must contain ≤0.2% dimeric impurity PF-00191189, adding a measurable quality/specification dimension to infringement analysis.
5) If litigation focuses on the API alone, which claims are the most direct?
Claim 1 (crystalline XRPD embodiments) and Claim 2 (amorphous solid) are the most direct substance claims, with Claim 13–15 providing additional hooks tied to Form IV identity and process-to-product manufacturing.
References
- U.S. Patent 11,084,780 (provided claim text).
